C. Seynaeve

1.7k citations

37 papers · 707 · h-index 16

Impact in

Oncology top 10%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Cancer Research
- Breast Cancer Treatment Studies

Papers in

Genetics 14
- BRCA gene mutations in cancer 9
- Estrogen and related hormone effects 4
Pulmonary and Respiratory Medicine 12
- Sarcoma Diagnosis and Treatment 6
- Advanced Breast Cancer Therapies 4

Co-authors: Jaap Verweij (11 shared papers)PHM de Mulder (2 shared papers)M. Bontenbal (6 shared papers)Ronald de Wit (2 shared papers)J.G.M. Klijn (5 shared papers)Iris van Oostrom (2 shared papers)Aad Tibben (3 shared papers)Rolf H. Sijmons (2 shared papers)
Journals: European Journal of Cancer (7 papers)Cancer Research (3 papers)Annals of Oncology (2 papers)Journal of Clinical Oncology (2 papers)Obstetrical & Gynecological Survey (1 paper)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

C. Seynaeve

36 papers receiving 665 citations

Peers

Countries citing papers authored by C. Seynaeve

Since Specialization

Citations

This map shows the geographic impact of C. Seynaeve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Seynaeve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Seynaeve more than expected).

Fields of papers citing papers by C. Seynaeve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Seynaeve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Seynaeve. The network helps show where C. Seynaeve may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Seynaeve, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Seynaeve Line = papers co-authored together C. Seynaeve links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study British Journal of Cancer ·(unknown), C. Seynaeve, Jan C. Schuller, K. Buser, H Porteder, S Van Belle, P. Sevelda, D Christmann, M Schmidt, Henry C Kitchener, D. Paes, PHM de Mulder	1992	82
2	Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study Clinical Genetics ·Iris van Oostrom, Hanne Meijers‐Heijboer, H.J. Duivenvoorden, A Bröcker-Vriends, CJ van Asperen, Rolf H. Sijmons, C. Seynaeve, AR Van Gool, J.G.M. Klijn, Aad Tibben	2006	65
3	Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane Breast Cancer Research and Treatment ·Carolien H. Smorenburg, M. Bontenbal, C. Seynaeve, C. van Zuylen, Gerda de Heus, Jaap Verweij, Ronald de Wit	2001	64
4	Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Research ·SE Jones, C. Seynaeve, Annette Hasenburg, D Rae, Jean-Michael Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Hein Putter, E.T.M. Hille, D.G. Kieback, Lina Asmar, Jan Smeets, R. Urbanski, JM Bartlett, CJ van de Velde	2009	54
5	A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours European Journal of Cancer ·Jean‐Yves Blay, Axel Le Cesne, Jaap Verweij, Michelle Scurr, C. Seynaeve, Sylvie Bonvalot, Pancras C.W. Hogendoorn, J. Jimeno, V. Evrard, M. van Glabbeke, Ian Judson	2004	46
6	Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing Annals of Oncology ·Iris van Oostrom, Hanne Meijers-Heijboer, H.J. Duivenvoorden, A Bröcker-Vriends, Christi J. van Asperen, Rolf H. Sijmons, C. Seynaeve, Arthur R. Van Gool, J.G.M. Klijn, Aad Tibben	2006	41
7	Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Cancer Research ·Daniel Rea, Annette Hasenburg, C. Seynaeve, SE Jones, J.M. Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Hein Putter, E.T.M. Hille, Lina Asmar, R. Urbanski, C. van de Velde, John M.S. Bartlett, Jan Smeets, D.G. Kieback	2009	33
8	Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin Sarcoma ·Astrid W. Oosten, C. Seynaeve, P.I.M. Schmitz, Michael A. den Bakker, Jaap Verweij, Stefan Sleijfer	2009	32
9	Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. International Journal of Clinical Oncology ·Jaap Verweij, S.M. Lee, W. Ruka, J. Buesa, Robert L. Coleman, Q.G.C.M. van Hoesel, C. Seynaeve, Eugenio Donato Di Paola, M. van Glabbeke, D. Tonelli, Ian Judson	2000	30
10	Relevant impact of central pathology review on nodal classification in individual breast cancer patients Annals of Oncology ·J.H.M.J. Vestjens, Manon J. Pepels, Maaike de Boer, George F. Borm, Carolien H. M. van Deurzen, P. J. van Diest, J.A.A.M. van Dijck, Eddy Adang, J.W.R. Nortier, Emiel J. Rutgers, C. Seynaeve, Marian B. E. Menke‐Pluymers, Peter Bult, Vivianne C. G. Tjan‐Heijnen	2012	27
11	5-HT3 receptor antagonists, a new approach in emesis Anti-Cancer Drugs ·C. Seynaeve, Jaap Verweij, PHM de Mulder	1991	25
12	Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. PubMed ·L.C. Verhoog, E. Berns, Cecile T.M. Brekelmans, C. Seynaeve, E.J. Meijers-Heijboer, J.G.M. Klijn	2000	23
13	Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer European Journal of Cancer and Clinical Oncology ·Ronald de Wit, Margot Tesselaar, T.C. Kok, C. Seynaeve, C. J. Rodenburg, Jaap Verweij, P.A. Helle, G. Stoter	1991	23
14	Cytotoxic therapy for the elderly with metastatic breast cancer: A review on safety, pharmacokinetics and efficacy European Journal of Cancer ·Paul Hamberg, Jaap Verweij, C. Seynaeve	2007	22
15	High-dose chemotherapy in adult sarcomas: no standard yet. PubMed ·C. Seynaeve, Jaap Verweij	1999	18
16	671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC) European Journal of Cancer Supplements ·M. Bontenbal, J.J. Braun, G.J. Creemers, A C de Boer, Jan Janßen, Mark Leys, Kristel L. Schothorst, P.I.M. Schmitz, J.J. Bokma, C. Seynaeve	2003	17
17	Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) Journal of Clinical Oncology ·M. Bontenbal, C. Seynaeve, Jacqueline M. Stouthard, M. Bos, Hans‐Joachim Braun, F. Erdkamp, Gert van Deijk, P.I.M. Schmitz, I. Van der Stelt-Frissen, Paul Hamberg, J.G.M. Klijn	2008	15
18	Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear Pharmacy World & Science ·C. Seynaeve, P.H.M. de Mulder, Jaap Verweij	1991	12
19	Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists' group (BOOG). Cancer Research ·Maaike de Boer, CH van Deurzen, JA van Dijck, GF Borm, PJ van Diest, E. M. Adang, HW Nortier, EJ Rutgers, C. Seynaeve, M. Menke-Pluymers, Peter Bult, VC Tjan-Heijnen	2009	9
20	Survival and Tumour Characteristics of Breast-Cancer Patients with Germline Mutations of BRCA1 Obstetrical & Gynecological Survey ·L.C. Verhoog, Cecile T.M. Brekelmans, C. Seynaeve, L. M. C. van den Bosch, G Dahmen, A.N. van Geel, Madeleine M.A. Tilanus‐Linthorst, C.C.M. Bartels, A. Wagner, AMW van den Ouweland, Peter Devilee, E.J. Meijers-Heijboer, J.G.M. Klijn	1998	9

About C. Seynaeve

C. Seynaeve is a scholar working on Genetics, Pulmonary and Respiratory Medicine, Oncology, Surgery and Cancer Research, having authored 37 papers that have together received 707 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (9 papers), Cancer Treatment and Pharmacology (7 papers), Sarcoma Diagnosis and Treatment (6 papers), Breast Cancer Treatment Studies (6 papers), Nausea and vomiting management (5 papers), Advanced Breast Cancer Therapies (4 papers), Estrogen and related hormone effects (4 papers) and Vascular Tumors and Angiosarcomas (4 papers). The work is most often cited by research in Oncology (250 citations), Cancer Research (135 citations), Genetics (191 citations), Pulmonary and Respiratory Medicine (136 citations) and Gastroenterology (23 citations). C. Seynaeve has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jaap Verweij, PHM de Mulder, M. Bontenbal, Ronald de Wit, J.G.M. Klijn, Iris van Oostrom, Aad Tibben, Rolf H. Sijmons, H.J. Duivenvoorden and A Bröcker-Vriends. Their work appears in journals such as European Journal of Cancer, Cancer Research, Annals of Oncology, Journal of Clinical Oncology and Obstetrical & Gynecological Survey.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

C. Seynaeve

Impact in

Papers in i

In The Last Decade

C. Seynaeve

Peers

Countries citing papers authored by C. Seynaeve

Fields of papers citing papers by C. Seynaeve

All Works

About C. Seynaeve

Explore authors with similar magnitude of impact

Papers in